Synchronization of extraction and chromatographic conditions of diverse physicochemical behavior of pseudoephedrine, loratadine and desloratadine for their simultaneous determination in human plasma: Application to pharmacokinetic study
Ehab F. Elkady,Rawda M. Sayed
DOI: https://doi.org/10.1016/j.microc.2024.112134
IF: 5.304
2024-11-16
Microchemical Journal
Abstract:A selective, sensitive, and rapid LC-MS/MS method has been developed, optimized, and validated for the simultaneous determination of pseudoephedrine (PSE), loratadine (LOR), and LOR active metabolite, desloratadine (DES) in K 3 EDTA human plasma. A simple liquid–liquid extraction method was adopted for extraction of the 3 analytes and their internal standards; chlorpheniramine (CLP), loratadine D4 (LOR-D4), and desloratadine D4 (DES-D4), respectively, giving consistent recovery results (78.38––88.23 %) using diethyl ether: dichloromethane (80:20, v/v ) as the extraction solvent. The chromatographic separation was challenging due to the polarity differences between PES, which is more polar, and LOR and DES, which are less polar that affected their physicochemical properties including the retention of the drugs on C18 column. The separation was achieved using of isocratic elution of 20 mM ammonium formate and 2 mM trifluoracetic acid ammonium salt: acetonitrile containing 0.15 % formic acid (12:88, v/v ) as a mobile phase pumped onto a Supelco Discovery® C18 (4.6 mm x 100 mm, 5 μm) column at 35 °C with a flow rate of 0.8 mL/min. The use of trifluoracetic acid ammonium salt as an ion pair reagent in the selected mobile phase allowed good retention of the polar PSE on the used C18 column with a reasonable retention time. Positive Electrospray ionization was employed followed by detection using a tandem mass spectrometer in multiple reactions monitoring (MRM) mode. The sample analysis of this study was conducted in compliance with ICH guideline M10 on bioanalytical method validation and study sample analysis. The method was linear over the concentration range of (4–1200) ng/mL for PSE, (50–15000) pg/mL for both LOR, and DES. The developed method was accurate (91.14–110.30 %), precise (0.53–7.86 %), and was applied to study the pharmacokinetic profile of the cited drugs in the plasma of healthy human volunteers after single oral administration of the fixed-dose combination Claritin D® tablet, (240/10 mg) of PSE, and LOR, respectively.
chemistry, analytical